ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Autorzy:
Yuan AL; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Ricks CB; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, United States of America. Bohm AK; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Lun X; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Maxwell L; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Safdar S; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Bukhari S; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Gerber A; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Sayeed W; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Oncology, University of Calgary, Calgary, Alberta, Canada. Bering EA; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Pedersen H; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Chan JA; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada. Shen Y; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Marra M; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Kaplan DR; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.; Program in Neurosciences and Mental Health, Hospital for Sick Children, Toronto, Ontario, Canada. Mason W; Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Goodman LD; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, United States of America. Ezhilarasan R; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, United States of America. Kaufmann AB; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, United States of America. Cabral M; Department of Neurosurgery, MD Anderson Cancer Center, Houston, Texas, United States of America. Robbins SM; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Oncology, University of Calgary, Calgary, Alberta, Canada. Senger DL; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Oncology, University of Calgary, Calgary, Alberta, Canada. Cahill DP; Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, United States of America. Sulman EP; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, United States of America. Cairncross JG; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.; Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. Blough MD; Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, Alberta, Canada.; Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.; Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Aug 28; Vol. 13 (8), pp. e0202860. Date of Electronic Publication: 2018 Aug 28 (Print Publication: 2018).
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Autorzy:
Williams EA; Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit street, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Miller JJ; Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit street, Boston, MA, USA.; Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA. Tummala SS; Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit street, Boston, MA, USA. Penson T; Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit street, Boston, MA, USA. Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Juratli TA; Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit street, Boston, MA, USA. Cahill DP; Translational Neuro-Oncology Laboratory, Department of Neurosurgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit street, Boston, MA, USA. cahill@mgh.harvard.edu.
The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study
Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.
Autorzy:
Tanaka S; Divisions of Neuro-Oncology and Hematology/Oncology, Harvard Medical School, Boston, Massachusetts, USA. .; Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, Japan. . Luk S; Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts, USA. Kiyokawa J; Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts, USA. Onozato ML; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Shah K; Center for Stem Cell Therapeutics and Imaging, Department of Neurosurgery, Brigham and Women's Hospital, Harvard medical School, Boston, Massachusetts, USA. Martuza RL; Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts, USA. Rabkin SD; Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts, USA. Batchelor TT; Divisions of Neuro-Oncology and Hematology/Oncology, Harvard Medical School, Boston, Massachusetts, USA. Cahill DP; Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts, USA. Chi AS; Divisions of Neuro-Oncology and Hematology/Oncology, Harvard Medical School, Boston, Massachusetts, USA.; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health and NYU School of Medicine, New York, NY, USA. Wakimoto H; Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Jan 15; Vol. 9 (1), pp. 139. Date of Electronic Publication: 2019 Jan 15.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.
Autorzy:
Tanaka S; Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Boston, USA.; Department of Neurosurgery, Boston, USA.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA.; The University of Tokyo Hospital, Tokyo, Japan. Batchelor TT; Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Boston, USA.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA.; Present Address: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Present Address: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Iafrate AJ; Translational Research Laboratory, Cancer Center, Boston, USA.; Department of Pathology, Boston, USA.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA. Dias-Santagata D; Translational Research Laboratory, Cancer Center, Boston, USA.; Department of Pathology, Boston, USA.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA. Borger DR; Translational Research Laboratory, Cancer Center, Boston, USA.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA. Ellisen LW; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA. Yang D; Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Boston, USA.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA. Louis DN; Department of Pathology, Boston, USA.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA. Cahill DP; Department of Neurosurgery, Boston, USA. cahill@mgh.harvard.edu.; Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114, USA. cahill@mgh.harvard.edu. Chi AS; Perlmutter Cancer Center, New York University Langone Health and School of Medicine, New York, USA. .; Present Address: Neon Therapeutics, 40 Erie Street, Suite 110, Cambridge, MA, USA. .
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
